# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ginkgo's Class A Common Stock continues to trade on the NYSEBOSTON, May 13, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, ...
William Blair analyst Matt Larew downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Market Perform to Underperform.
Ginkgo Bioworks reported quarterly sales of $38 million which missed the analyst consensus estimate of $46.044 million by 17.47...
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of...
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly sales of $38.000 million which missed the analyst consensus estimate of ...